Edgar Filing: GALECTIN THERAPEUTICS INC - Form 4

GALECTIN Form 4	THERAPEUT	ICS INC									
February 04	, 2014										
FORM	Λ4								OMB AF	PROVAL	
Washington, D.C. 20549						OMMISSION	OMB Number:	3235-0287			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction Section 17(a) of the Pub 30(h) of the Section 17(a) of the Section 17(b) of the Section				SECUR	e Securitiding Com	Act of 1934, 1935 or Section	Expires: January 3 200 Estimated average burden hours per response 0				
l(b).	Desmonaes)										
(Print or Type	Responses)										
Prelack Steven Symbo GAL			2. Issue Symbol	uer Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer			
			GALECTIN THERAPEUTICS INC [GALT]					(Check all applicable)			
(Last)	(Last) (First) (Middle) 3. Date of (Month/D				ansaction			X_ Director 10% Owner Officer (give title Other (specify			
INC., 4960	CTIN THERAN PEACHTREE IAL BLVD, ST		01/31/2	-				below)	below)		
(Street) 4. If Amen				ndment, Date Original th/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
								Person			
(City)	(State)	(Zip)	Tab	le I - Non-D	Derivative S	Securi	ties Acqu	iired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired Transactior(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	01/31/2014			Code V M	Amount 667	(D) A	Price \$ 0.72		D		
Common Stock	01/31/2014			М	83,334	A	\$ 1.2	86,937	D		
Common Stock	01/31/2014			М	9,260	А	\$ 6.48	96,197	D		
Common Stock	01/31/2014			М	8,475	А	\$ 7.08	104,672	D		
	01/31/2014			М	6,269	А	\$ 3.59	110,941	D		

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 4

Common Stock										
Common Stock	01/31/2	014	F	17,722 (9)	D	\$ 13.71	93,219	D		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not information contained in this form are not information contained to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned SEC 1474 (9-02)										
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(e.g., 3. Transaction Date (Month/Day/Year)	3A. Deemed	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		•ities) 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 0.72 <u>(1)</u>	01/31/2014		М		667 <u>(1)</u>	02/08/2009	02/08/2014	Common Stock	667
Stock Option (right to buy)	\$ 1.2 <u>(3)</u>	01/31/2014		М		83,334 (1)	<u>(2)</u>	02/25/2014	Common Stock	83,334
Stock Option (right to buy)	\$ 6.48 (<u>4)</u>	01/31/2014		М		9,260 (4)	<u>(5)</u>	03/24/2016	Common Stock	9,260
Stock Option (right to buy)	\$ 7.08 <u>(6)</u>	01/31/2014		М		8,475 (<u>6)</u>	(7)	06/28/2021	Common Stock	8,475
Stock Option (right to buy)	\$ 3.59	01/31/2014		М		6,269	(8)	03/28/2023	Common Stock	6,269

Reporting Owners

Reporting Ow	Relationships					
FB	Director	10% Owner	Officer	Other		
Prelack Steven C/O GALECTIN THERA 4960 PEACHTREE IND NORCROSS, GA 30071	APEUTICS INC. USTRIAL BLVD, STE 240	Х				
Signatures						
/s/ Steven Prelack	02/03/2014					

<u>**</u>Signature of Reporting Person Date

f

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was previously reported as covering 4,000 shares at an exercise price of \$0.12 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
- (2) Stock Option grant, vested as follows: (i) 50% on February 25, 2010; (ii) 25% on May 25, 2010; (iii) 12.5% on August 25, 2010; (iv) 6.25% on November 25, 2010; and (v) 6.25% on February 25, 2011.
- (3) This option was previously reported as covering 500,000 shares at an exercise price of \$0.2 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
- (4) This option was previously reported as covering 55,556 shares at an exercise price of \$1.08 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
- (5) The option vests in eight equal installments beginning May 12, 2011.
- (6) This option was previously reported as covering 50,848 shares at an exercise price of \$1.18 per share, but was adjusted to reflect the 1-for-6 reverse stock split that occurred in March 2012.
- (7) The option vests as to one-eighth of the shares on June 28, 2011 and thereafter quarterly in seven equal installments beginning August 12, 2011.
- (8) The option vests quarterly in eight equal installments beginning on May 12, 2013.
- (9) Represents shares forfeited in satisfaction of exercise price of vested options.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.